Your browser doesn't support javascript.
loading
Dyslipidemia and Rate of Under-Target Low-Density Lipoprotein-Cholesterol in Patients with Coronary Artery Disease in Korea.
Lee, Sang-Hak; Song, Woo-Hyuk; Jeong, Myung Ho; Hur, Seung-Ho; Jeon, Dong Woon; Jeung, Wonju; Gitt, Anselm K; Horack, Martin; Vyas, Ami; Lautsch, Dominik; Ambegaonkar, Baishali; Brudi, Philippe; Jang, Yangsoo.
Afiliação
  • Lee SH; Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
  • Song WH; Cardiovascular Division, Department of Internal Medicine, Korea University Ansan Hospital, Ansan, Korea.
  • Jeong MH; Department of Cardiovascular Medicine, Chonnam National University Hospital, Gwangju, Korea.
  • Hur SH; Department of Cardiology, Keimyung University Hospital, Daegu, Korea.
  • Jeon DW; Division of Cardiology, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Korea.
  • Jeung W; Merck Sharp & Dohme (MSD), Seoul, Korea.
  • Gitt AK; Stiftung Institut für Herzinfarktforschung, Ludwigshafen, Germany.
  • Horack M; Klinikum der Stadt Ludwigshafen, Medizinische Klinik B, Ludwigshafen, Germany.
  • Vyas A; Stiftung Institut für Herzinfarktforschung, Ludwigshafen, Germany.
  • Lautsch D; Department of Epidemiology, School of Public Health, Rutgers University, Piscataway, NJ, USA.
  • Ambegaonkar B; Merck & Co., Inc., Kenilworth, NJ, USA.
  • Brudi P; Merck & Co., Inc., Kenilworth, NJ, USA.
  • Jang Y; Merck & Co., Inc., Kenilworth, NJ, USA.
J Lipid Atheroscler ; 8(2): 242-251, 2019 Sep.
Article em En | MEDLINE | ID: mdl-32821714
ABSTRACT

OBJECTIVE:

The aim of this study was to evaluate under target rates of low-density lipoprotein-cholesterol (LDL-C) in Korean patients with stable coronary artery disease (CAD) or an acute coronary syndrome (ACS) in real world practice.

METHODS:

Dyslipidemia International Study II was an international observational study of patients with stable CAD or an ACS. Lipid profiles and use of lipid-lowering therapy (LLT) were documented at enrollment, and for the ACS cohort, 4 months follow-up was recommended. Rates of under target LDL-C as per European guidelines, were evaluated, and multivariate regression was performed to identify predictive factors of patients presenting under the target.

RESULTS:

A total of 808 patients were enrolled in Korea, 500 with stable CAD and 308 with ACS. Of these, 90.6% and 52.6% were being treated with LLT, respectively. In the stable CAD group, 40.0% were under target LDL-C, while in ACS group, the rate was 23.7%. A higher statin dose was independently associated with under target LDL-C in both groups (OR, 1.03; p=0.046 [stable CAD] and OR, 1.05; p=0.01 [ACS]). The mean statin dosage (atorvastatin equivalent) was 17 mg/day. In the 79 ACS patients who underwent the follow-up examination, the LDL-C under target rate rose to 59.5%.

CONCLUSION:

Only a minority of patients with stable CAD or ACS were under their target LDL-C level at enrollment. The statin dose was not sufficient in the majority of patients. These results indicate a considerable LLT gap in Korean patients with established CAD.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Observational_studies / Prognostic_studies Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Observational_studies / Prognostic_studies Idioma: En Ano de publicação: 2019 Tipo de documento: Article